| Authors: |
Buckley NA; MRC Toxicology Unit, University of Cambridge, Cambridge, UK.; Safety Sciences, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Craxton A; MRC Toxicology Unit, University of Cambridge, Cambridge, UK., Sun XM; MRC Toxicology Unit, University of Cambridge, Cambridge, UK., Panatta E; MRC Toxicology Unit, University of Cambridge, Cambridge, UK.; Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy., Pinon LG; MRC Toxicology Unit, University of Cambridge, Cambridge, UK., Beier S; MRC Toxicology Unit, University of Cambridge, Cambridge, UK., Kalmar L; MRC Toxicology Unit, University of Cambridge, Cambridge, UK., Llodrá J; MRC Toxicology Unit, University of Cambridge, Cambridge, UK., Morone N; MRC Toxicology Unit, University of Cambridge, Cambridge, UK., Amelio I; MRC Toxicology Unit, University of Cambridge, Cambridge, UK.; Division for Systems Toxicology, Department of Biology, University of Konstanz, Konstanz, Germany., Melino G; MRC Toxicology Unit, University of Cambridge, Cambridge, UK.; Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy., Martins LM; MRC Toxicology Unit, University of Cambridge, Cambridge, UK. lm795@cam.ac.uk., MacFarlane M; MRC Toxicology Unit, University of Cambridge, Cambridge, UK. mm2312@mrc-tox.cam.ac.uk. |
